caa a22 4500 477072615 CHVBK 20180405111430.0 cr unu---uuuuu 170330e19961101xx s 000 0 eng 10.1007/BF00050991 doi (NATIONALLICENCE)springer-10.1007/BF00050991 Clinical aspects of ACE inhibition in patients with acute myocardial infarction [Elektronische Daten] [Claudio Borghi, Ettore Ambrosioni] Summary: The purpose of the present article was to review the current evidence on the use of angiotensin-converting enzyme (ACE) inhibitors in acute myocardial infarction (MI). This article is based on published information as well as on our personal experience derived from an extensive analysis of the SMILE study. All the randomized trials have been included irrespective of the primary endpoint, and the results are presented in terms of either hemodynamic or clinical benefit. Short- and long-term treatment with ACE inhibitors in patients with acute MI results in a significant reduction in mortality, which is more evident in high risk patients (i.e., patients with left ventricular dysfunction, congestive heart failure on admission, or anterior myocardial infarction). Development and progression of congestive heart failure after myocardial infarction was significantly reduced by ACE inhibition, which also reduced the rate of reinfarction, the need for revascularization procedures, as well as the occurrence of ventricular arrhythmias, probably through a mechanism involving some drug-dependent effects. In conclusion, the available data strongly support a wide benefit associated with the use of ACE inhibitors in patients with high-risk acute MI. Kluwer Academic Publishers, 1996 ACE inhibitors nationallicence myocardial infarction nationallicence heart failure nationallicence angiotensin-converting enzyme inhibitors nationallicence Borghi Claudio Department of Medicine, University of Bologna, Bologna, Italy aut Ambrosioni Ettore Department of Medicine, University of Bologna, Bologna, Italy aut Cardiovascular Drugs and Therapy Kluwer Academic Publishers 10/5(1996-11-01), 519-525 0920-3206 10:5<519 1996 10 10557 https://doi.org/10.1007/BF00050991 text/html Onlinezugriff via DOI 1 review-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00050991 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Borghi Claudio Department of Medicine, University of Bologna, Bologna, Italy aut NATIONALLICENCE 700 1- Ambrosioni Ettore Department of Medicine, University of Bologna, Bologna, Italy aut NATIONALLICENCE 773 0- Cardiovascular Drugs and Therapy Kluwer Academic Publishers 10/5(1996-11-01), 519-525 0920-3206 10:5<519 1996 10 10557 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer